Skip to main content

Table 4 Adverse events in objective blood tests during the treatment and sequelae at the 10th week in patients between group I and group II

From: Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure

 

Group I (AmB+

Group II (AmB+

P-value

Fluconazole + 5-FC)

Fluconazole + 5-FC + VPS)

Adverse events (n, %)

(n = 27)

(n = 39)

 

 Hypokalemia

13 (48.1%)

20 (51.3%)

0.804

 Transaminase elevation

14 (51.9%)

15 (38.5%)

0.285

 Renal impairment

5 (18.5%)

12 (30.8%)

0.267

 Hematological impairment

5 (18.5%)

14 (35.9%)

0.128

Sequelae

(n = 27)

(na = 36)

 

 Headache

9 (33.3%)

9 (25.0%)

0.395

 Dizziness/vertigo

2 (7.4%)

5 (13.9%)

0.465

 Hemiparesis

4 (14.8%)

5 (13.9%)

0.850

 Visual

8 (29.6%)

6 (16.7%)

0.184

 Auditory

1 (3.7%)

7 (19.4%)

0.077

 Seizure

3 (11.1%)

2 (5.6%)

0.387

  1. a One patient was lost to -follow-up and two patients were death at the 10th week in Group II
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us